when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GILEAD · news · pharmadog

← back to GILEAD

News mentioning GILEAD

190 stories

13dGilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I pushbiospace

13dSTAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis findsstat

13dOpinion: I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lyingstat

13dGilead’s pill posts stronger colitis remission rates than Entyvioendpoints

13dSTAT+: China moves to restrict foreign biotech acquisitionsstat

14dSTAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and morestat

14dGilead ‘sitting on a foundational asset’ after oral UC drug's phase 2 winfiercebiotech

14dSTAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study findsstat

17dBelgian startup revives Galapagos CAR-T researchbiopharma dive

17dStoffels strikes up new biotech in return to Galapagos cell therapy missionbiospace

18dSTAT+: On Wall Street, there’s trouble stirring for biotechstat

18dRebranded Galapagos finally finds buyer for unwanted cell therapy pipelinefiercebiotech

18dAstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugsfiercebiotech

18dGilead snags equity stake in Vir with up to $1.87B deal for three T cell engagersbiospace

19dJ&J earnings set ‘negative tone’; Shkreli vs. the FTCbiopharma dive

19dVir makes solid tumor T cell engager deal with Gileadendpoints

19dVir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsfiercebiotech

19dMerck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancerfiercebiotech

23dParkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsfiercebiotech

23dParkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOsendpoints

24dViking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansionendpoints

27dBioSpace 40 Under 40 winners make their mark on biopharmabiospace

Oct 2, 26Novartis wagers almost $8B on a Chinese biotech’s RNA drugsbiopharma dive

Oct 1, 26Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOfiercebiotech

Oct 1, 26STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapystat

Oct 1, 26STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may awaitstat

Sep 28, 26Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Virfiercebiotech

Sep 28, 26STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’stat

Sep 25, 26STAT+: Lilly wins approval for once-weekly insulin shotstat

Sep 25, 26J&J, Legend tout long-term survival benefits for Carvykti in multiple myelomabiospace

← prevpage 2 of 7next →